Early post-treatment with 9-cis retinoic acid reduces neurodegeneration of dopaminergic neurons in a rat model of Parkinson’s disease by Lian-Hu Yin et al.
Yin et al. BMC Neuroscience 2012, 13:120
http://www.biomedcentral.com/1471-2202/13/120RESEARCH ARTICLE Open AccessEarly post-treatment with 9-cis retinoic acid
reduces neurodegeneration of dopaminergic
neurons in a rat model of Parkinson’s disease
Lian-Hu Yin1,3, Hui Shen1, Oscar Diaz-Ruiz2, Cristina M Bäckman2, Eunkyung Bae1, Seong-Jin Yu1† and Yun Wang1*†Abstract
Background: Retinoic acid (RA) is a biologically active derivative of vitamin A. Previous studies have demonstrated
that RA has protective effects against damage caused by H2O2 or oxygen-glucose deprivation in mesangial and
PC12 cells. Pretreatment with 9-cis-retinoic acid (9cRA) reduced infarction and TUNEL labeling in cerebral cortex as
well as attenuated neurological deficits after distal middle cerebral artery occlusion in rats. The purpose of this
study was to examine a protective role of 9cRA in dopaminergic (DA) neurons in a typical rodent model of
Parkinson’s disease (PD).
Results: The protective role of 9cRA was first examined in rat primary ventromesencephalic culture. Treatment with
9cRA significantly reduced 6-hydroxydopamine (6-OHDA)-mediated cell death and TUNEL labeling in cultured
dopaminergic neurons. The protective effect was also examined in adult male rats. Animals received unilateral
6-OHDA lesioning at the left medial forebrain bundle on day 0. Methamphetamine -induced rotational behavior
was examined on days 6, 20 and 30 after lesioning. Animals were separated into 2 groups to balance rotational
behavior and lesion extent on day 6 and were treated with either 9cRA or vehicle (i.c.v. on day 7 + intra-nasal from
day 8 to day 14). Post-treatment with 9cRA significantly reduced methamphetamine –mediated ipislateral rotation
at 20 and 30 days after lesioning. In vivo voltammetry was used to examine DA overflow in striatum. Treatment
with 9cRA significantly increased KCl -evoked DA release in the lesioned striatum. 9cRA also increased tyrosine
hydroxylase (+) cell number in the lesioned nigra as determined by unbiased stereology.
Conclusion: Our data suggests that early post-treatment with 9cRA has a protective effect against
neurodegeneration in nigrostriatal DA neurons in an animal model of PD.Background
Retinoic acid (RA) is a biologically active derivative of vita-
min A. Two major isoforms of RA, all-trans RA (atRA)
and 9-cis RA (9cRA), have been identified. atRA is nor-
mally present at high levels in the developing spinal cord
and at low levels in the forebrain of mouse embryos
(Horton and Maden, 1995). On the other hand, 9cRA is
not present in mouse embryos [1-3] or tissue extracts
from adult rats [4]. RAs interact with two major groups of
nuclear receptors: retinoic acid receptors (RAR) and* Correspondence: ywang@intra.nida.nih.gov
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reproduction in any medium, provided the orretinoid X receptors (RXR). 9cRA binds with high affinity to
RXR [5], whereas both 9cRA and atRA activate RAR [6,7].
RA has been reported to have protective effects after
injury. RA inhibited H2O2-induced apoptosis via sup-
pression of c-fos/c-jun expression and JNK activation in
mesangial cells [8] and increased survival during anoxia/
glucose deprivation in PC12 cells [9]. These data suggest
that RA can induce protective responses in cultured
cells. The function of RA in the mature nervous system
is less documented. Pretreatment with docosahexaenoic
acid (DHA), a candidate ligand for RXR [10], reduced
cerebral infarction induced by middle cerebral artery oc-
clusion [11,12]. We previously reported that 9cRA is
more potent than atRA in reducing ischemia –mediated
brain infarction [13] and, furthermore, pretreatment
with 9cRA attenuated DNA fragmentation in the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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gether, these data suggest that 9cRA is neuroprotective
against cerebral ischemia in vivo.
Several reports also indicate that RA can reduce de-
generation induced by dopaminergic neurotoxins in cul-
ture. RA attenuates 6-hydroxydopamine (6-OHDA) and
1-methyl-4-phenylpyridinium (MPP+) -mediated neuro-
toxicity in SY5Y neuroblastoma cells [15]. The protective
effects of RA in these cells involves the Akt pathway, in-
creasing BCL2 while reducing p53 levels [15,16]. In rat
midbrain slice cultures, treatment with a RAR agonist
AM80 prevents IFN-r/LPS –induced dopaminergic cell
loss [17]. These data suggest that RA has protective
effects in dopaminergic neurons in culture. One recent
study has shown that systemic administration of a high
dose of RA (1mg/kg, i.p.) for 15 days reversed rotenone
–induced impairment of locomotor activity without sig-
nificantly reversing the reduction of dopamine (DA) in
striatum [18]. In most of these studies, atRA was used to
examine the protective effect of RA against dopamin-
ergic neurotoxins. The protective role of 9cRA in dopa-
minergic neurons in an established model of PD has not
been reported.
9cRA has also been shown to induce protection in ani-
mal model of stroke [13,14]. Application of a similar
dose of atRA did not reduce the size of infarction after
middle cerebral artery occlusion in rats, suggesting that
9cRA is more potent than atRA in neuroprotection [13].
Unlike atRA, 9cRA regulates the expression of proteins
in the transforming growth factor (TGF) -β superfamily.
9cRA enhances production of glial cell line derived
neurotrophic factor (GDNF), and bone morphogenetic
protein-7 (BMP-7) protein [14], in human neuroblast-
oma cells and U2 OS cells, respectively. 9cRA also
increases midkin mRNA in primary cortical neurons
[13]. All these trophic factors or proteins have been
reported to reduce stroke insults [13,19,20].
We previously demonstrated that intracerebroventri-
cular administration of 9cRA time-dependently upregu-
lates BMP7 mRNA expression in rodent brain [14]. The
9cRA –mediated reduction in cerebral infarction in
stroke rats was significantly antagonized by the BMP an-
tagonist noggin [14], suggesting that 9cRA induces pro-
tection through BMP7. Interestingly, BMP7 has been
shown to reduce dopaminergic neurotoxins –mediated
neurodegeneration in vivo and in vitro. BMP7 signifi-
cantly reduced rotational behavior, partially preserved
KCl- induced DA release in the lesioned striatum, and
increased tyrosine hydroxylase (TH) immunoreactivity
in lesioned nigra in unilaterally 6-OHDA -lesioned rats
[21]. Similarly, BMP7 antagonized high dose metham-
phetamine –induced DA cell loss in cultured dopamin-
ergic neurons and striatal TH fiber density reduction
in vivo [22]. Knocking down BMP7 or BMPRII receptorsexpression in mice increased sensitivity to dopaminergic
neurotoxins in nigrostriatal dopaminergic neurons
[22,23]. These data suggest that BMP7 has protective
effects against DA-ergic neurotoxin –mediated degener-
ation. Since 9cRA enhances BMP7 expression, we rea-
soned it may also induce protection against 6-OHDA
lesioning in an animal model of Parkinson’s disease (PD)
through the BMP7 pathway.
In this study, we examined the protective effect of
9cRA in a rodent animal model of PD. 9cRA was given
at low dose from 7 days after unilateral 6-OHDA lesion-
ing in adult rats. We found that post-treatment with
9cRA significantly reduced rotational behavior while
increased the survival of dopamine cells in the lesioned
nigra and KCl-evoked DA release in lesioned striatum.
Our data suggest that 9cRA induces neuroprotection
against neurodegeneration in nigrostriatal DA neurons
in an animal model of PD.
Results
VM cell cultures
We first examined protective effects of 9cRA in ventro-
mesenphalic (VM) neuronal culture. Cells were fixed at
24 hours after 6-OHDA treatment. Typical TH immu-
noreactivity of VM cultured cells is demonstrated in
Figure 1A. Treatment with 6-OHDA dose-dependently
reduced TH (+) cell density (Figure 1B, p<0.001, two
way ANOVA). 9cRA or vehicle was given at 2 hours
after addition of 6-OHDA or vehicle to the well. Treat-
ment with 9cRA (50 nM) did not alter TH cell density
in non-lesioned cells; however, 9cRA significantly atte-
nuated 6-OHDA-medated loss of TH cells at 24 hours
after lesioning (Figure 1B, p=0.022, two way ANOVA).
We also found that 6-OHDA treatment enhanced the
density of TUNEL labeling. 9cRA significantly reduced
6-OHDA –mediated TUNEL activity (Figure 1C and D,
p<0.001, one way ANOVA + Newman-Keuls test).
We previously demonstrated that 9cRA is more potent
than atRA against ischemic brain injury in vivo. Simi-
larly, we found that 9cRA is more efficient that atRA
against 6-OHDA –mediated neurodegeneration in VM
TH neurons. More TH neurons survived post-treated
with 9cRA, compared to atRA, after 6-OHDA lesioning
(Figure 2, p<0.001, t test).
Animal study
(A) Rotation
A total of 17 rats received unilateral 6-OHDA lesioning
on day 0. Methamphetamine -induced rotational behavior
was examined on days 6, 20 and 30 after 6-OHDA lesion-
ing. Animals were separated into 2 groups (veh and 9cRA)
to equalize group rotational behavior and thus lesion
extent on day 6. Two animals were excluded because the
rotation was higher than 960 turns/hour to avoid maximal
Figure 1 9cRA reduces 6-OHDA-induced toxicity in ventral mesencephalic cultures. (A) Primary cultures prepared from rat VM (E15) were
treated with 6-OHDA (0, 30, 100 μM) for two hours then washed and exposed to vehicle or 9cRA for 22 hours. Cells were fixed and assayed using
TH immunostaining. 9cRA (50 nM) alone did not alter the TH (+) neurons in culture; however, it antagonized the 6-OHDA-mediated decrease in
TH cell density. (B) A dose-dependent effect of 6-OHDA on loss of TH cells. Treatment with 9cRA (50 nM) significantly antagonized the loss
TH cells induced by 6-OHDA (*p<0.05, 2- way ANOVA). The density of TH (+) cells was normalized to the cell density in the non-6-OHDA and
non-9cRA (vehicle) -treated group. (C) 9cRA reduced 6-OHDA (100 μM) –mediated TUNEL labeling in VM neuronal culture. (D) Averaged TUNEL
density per field. All data were normalized to the mean of TUNEL density in 6-OHDA +veh group. Treatment with 9cRA (50 nM) significantly
reduced 6-OHDA- mediated TUNEL activity to control levels (*p<0.001, 1- way ANOVA).
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no difference in rotation prior to 9cRA or vehicle treat-
ment between these two groups (p=0.789, t test). Aver-
aged rotation (turns/hour) was 494.1 +/− 73.6 (for RA
group, n=7) and 523.6 +/− 77.6 (for veh group, n=8). Ani-
mals were treated with 9cRA or veh from day 7 to day 14
(Figure 3). The rotational behavior was re-examined on
days 20 and 30 after lesioning (Figure 3). Using a two way
ANOVA, we determined that 9cRA, compared to vehicle,
significantly reduced methamphetamine -mediated rotationin the unilaterally 6-OHDA-lesioned rats (p=0.028,
Figure 3).
(B) KCl-induced DA release and DA clearance in striatum
KCl-evoked DA release in striatum was examined using
in vivo voltammetry in 11 rats at >2 months after unilat-
eral 6-OHDA injection. Five of these animals were treated
with 9cRA and the other six were treated with vehicle.
KCl-evoked DA release was recorded in 143 striatal sites
between 3.5 mm to 7.0 mm below the brain surface and
Figure 2 9cRA is more effective than atRA against 6-OHDA –mediated neurodegeneration in VM TH neurons. (A) Primary VM neuronal
cultures were treated with either 6-OHDA (100 μM) or saline for two hours and then were treated with either 9cRA or atRA (50 nM). 9cRA,
compared to atRA, is more potent in protecting against 6-OHDA –mediated loss of TH cells). (B) 9cRA (50 nM) is significantly effective than atRA
(50 nM) to increase survival of TH cells after lesioning with 6-OHDA (100 μM). The density of TH (+) cells was normalized to the cell density
in the non-6-OHDA and non-9cRA (vehicle) -treated group. More TH neurons survived after treatment with 9cRA+ 6-OHDA, compared to
atRA + 6-OHDA (*p<0.001).
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80 sites were taken from the striatum ipsilateral (L) to the
6-OHDA injection while 44 sites were recorded in the
contralateral (R) striatum. Average dose of KCl ejected
from micropipette was 204.0 ± 9.1 nl per site. Local appli-
cation of KCl resulted in release of dopamine in all sites in
non-lesioned (R) striatum in both 9cRA and vehicleFigure 3 Post-treatment with 9cRA reduced methamphetamine
–induced ipislateral rotation in hemiparkinsonian rats. Animals
were lesioned by local administration of 6-OHDA at the left medial
forebrain bundle on day 0. Rotation was induced by administration
of 2.5 mg/kg methamphetamine at day 6 (prior treatment) and days
20 and 30 (after treatment). Treatment with 9cRA from day 7 to day
14 (i.c.v. and intranasal) significantly reduced rotation. Bar on X-axis
represents the period animals received 9cRA or vehicle.-treated mice. On the other hand, the peak of DA release
was reduced in the lesioned striatum. Typical extracellular
dopamine tracings from left and right striatum are shown
in Figure 4.
Previous voltammetric studies have shown a dose re-
sponse relationship between the peak of extracellular
DA level and log dose of applied DA through a micro-
pipette in rat striatum [24,25]. In this study, the ampli-
tude of DA release was thus normalized by comparison
to the log volume (in nL) of KCl used. A similar ap-
proach has been used in our previous papers [26,27].
There is a significant reduction in KCl-evoked DA re-
lease in the lesioned striatum, compared to the non-
lesioned striatum (Figure 5, p<0.001, one way ANOVA;
p<0.001) in both vehicle and 9cRA treated animals
(p<0.001, post-hoc Newman Keuls test). However, treat-
ment with 9cRA significantly increased KCl-evoked DA
release in the lesioned side striatum (p=0.041;
Figure 5A), compared to vehicle. No difference was
found in the non-lesioned side striatum between 9cRA
and vehicle –treated animals (p=0.263).
The rate of DA clearance (nM per sec) after KCl appli-
cation was calculated by measuring the slope between
T20 and T60 (Figure 4A) of the DA currents, as
described previously [27,28]. There was a significant re-
duction of DA clearance in the lesioned side striatum
(Figure 5B, p<0.001, one way ANOVA; p<0.001, post-
hoc Fisher LSD test). Treatment with 9cRA significantly
increased DA clearance rate in the lesioned side striatum
(p=0.028; Figure 5B) compared to vehicle.
Figure 4 Typical voltammetric tracings of extracelluar DA concentration in dorsal striatum in unilaterally 6-OHDA lesioned rats.
Examples of KCl -evoked dopamine release were taken from dorsal striatum (3.5 to 5 mm below brain surface). KCl (150–200 nL x 70 mM) was
delivered locally through a micropipette next to DA sensor at time 0. (A) Local administration of KCl induced DA release in non-lesioned striatum
(black tracing) in a vehicle treated animal. In the same animal, KCl-mediated DA release was almost abolished in lesioned striatum (red tracing).
(B) In contrast, 9cRA treatment partially restored KCl –induced DA release in lesioned striatum in another animal. 9cRA did not alter DA release in
the non-lesioned striatum. Note that slope between T20 and T60 (A) is used to calculate the rate of clearance in Figure 5B.
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TH immunoreactivity was studied at >2 months after
unilateral 6-OHDA lesioning, TH-positive [TH (+)] cell
number in SN and in VTA were counted in 11 rats.
Typical TH immunostaining of 6-OHDA -lesioned ani-
mals receiving either 9cRA or vehicle treatment is
shown in Figure 6. Injection of 6-OHDA consistently
reduced TH (+) cell number in SN in either vehicle or
9cRA –treated animals (p<0.001, 2-Way ANOVA;
p<0.001, post-hoc Newman Keuls test, Figure 7A).
Treatment with 9cRA significantly increased TH (+) cell
number in the lesioned side SN (p=0.026, post-hoc New-
man Keuls test) compared to vehicle. No change was
found in the contralateral (non-lesioned) side SN
(p=0.432). Although there is a trend that A10 TH cell
number can be suppressed by 6-OHDA lesioning, there
is no significant difference after lesioning or after 9cRA
treatment (Figure 7B, p=0.734).
Discussion
In this study, we found that density of TH (+) neurons
and fibers in primary VM cultures were dose depend-
ently reduced at 2 days after 6-hydroxydopamine treat-
ment. 6-OHDA also induced DNA fragmentation as
demonstrated in TUNEL labeling. These data are in
agreement with our previous studies and suggest that
administration of 6-OHDA causes activation of apop-
totic pathways that lead to the death of VM dopamin-
ergic neurons. We found that early and post treatment
with 9cRA reduced 6-OHDA -mediated injury in VM
cells. 6-OHDA -mediated reduction of TH cell densitywas significantly antagonized by 9cRA, suggest-
ing that 9cRA is neuroprotective against 6-OHDA
-mediated neurodegeneration in dopaminergic neurons
in vitro.
Previous studies have demonstrated that RA exerts
anti-apoptotic and antioxidant activity in neuronal and
kidney cells. RA reduced staurosporine-induced oxida-
tive stress and apoptosis by preventing the decrease in
the levels of Cu-,Zn-superoxide dismutase (SOD-1) and
Mn-superoxide dismutase (SOD-2) in primary hippo-
campal cultures [29] and by facilitating NGF-induced
protection in chick embryonic neurons [30]. RA sup-
pressed hydrogen peroxide –induced apoptotic nuclear
condensation and membrane blebbing in rat glomeruli
mesangial cells. Our recent studies also indicated that
9cRA reduced the density of TUNEL labeling, a marker
for apoptosis/necrosis in ischemic cortex after middle
cerebral artery occlusion in rats [14]. In this study, we
demonstrated that treatment with 9cRA reduced 6-
OHDA-mediated DNA fragmentation in culture. Taken
together, our data suggest that 9cRA inhibits apoptosis
and/or necrosis induced by 6-OHDA.
Using an established rodent model of PD, we also
demonstrated the protective effect of 9cRA in vivo. Ad-
ministration of amphetamine analogs causes ipislateral
rotation in unilaterally 6-OHDA -lesioned rats due to
differential increase of dopaminergic activity on the in-
tact side. There is a correlation between amphetamine–
induced ipislateral rotation and the depletion of dopamine
in the nigra [31]. In this study, 9cRA was given after rota-
tion experiment on day 6 post lesioning. We separated
Figure 5 Averaged DA release (A) and rate of DA clearance (B) in striatum in 9cRA or vehicle treated hemiparkinsonian rats. (A) The
peak amplitude of the DA signal, induced by local KCl administration, was averaged in lesioned (L, left) or non-lesioned (R, right) striatum of
unilaterally 6-OHDA -lesioned rats. KCl-evoked DA release was almost abolished in the L striatum in vehicle treated rats. Treatment with 9cRA
significantly increased DA release in the lesioned striatum. (B) The rate of DA clearance (nM/s) after KCl application was calculated between T20
and T60. There is a significant reduction in DA clearance in the striatum ipsilateral to the 6-OHDA lesioning in vehicle treated rats. 9cRA treatment
significantly enhanced rate of DA clearance.
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fore treatment; the difference in lesioning prior to
treatment was thus minimal between two groups. We
demonstrated that post-treatment with 9cRA, com-
pared to vehicle, significantly attenuated rotation. Our
data support that early and post-treatment with 9cRA
reduced behavioral imbalance in hemiparkinsonian rats.
The protective effect of 9cRA is further supported by
in vivo electrochemical data at 2 months after lesioning.
We used high speed chronoamperometry to examine thetime course of KCl -evoked DA release and clearance in
striatum. The dose of KCl applied locally was between
7–14 × 10-11 mole (70 mM × 204.0 ± 9.1 nl) per site.
The dose, concentration and volume of the KCl solution
have been previously reported to induce depolarization
and release of dopamine at dopaminergic nerve term-
inals in vivo [26,32]. We found that local administration
of KCl induced DA release equally in the non-lesioned
side striatum in 9cRA or vehicle –treated rats. In the
lesioned side striatum, KCl-evoked DA release and the
Figure 6 Post-treatment with 9cRA attenuated the loss of TH cells in nigra. TH immunoreactivity was conducted at >2 months after
unilateral 6-OHDA lesioning. (A) Almost no TH activity was found in the lesioned side nigra (left panel, rostral nigra; middle and right panels,
caudal nigra) in 3 vehicle treated animals. Treatment with 9cRA partially blocked the loss of TH immunoreactivity in another 3 lesioned rats. (B)
Labels in each panel correspond to the blocks at higher magnification in (A). Note that almost no TH cells in lesioned SN in the vehicle treated
rat (B-a). In contrast, TH (+) cells were found in rostral (B-b) and caudal (B-c,d) SN in the lesioned rats treated with 9cRA.
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receiving vehicle treatment. Treatment with 9cRA did
not induce a full recovery but significantly increased
KCl-evoked DA release and DA clearance in the lesioned
side striatum. These electrochemical data support that
post-treatment with 9cRA protects against 6-OHDA
–mediated deficiency in DA function in striatum.
Using unbiased stereology, we demonstrated that post-
treatment with 9cRA significantly reduced the loss ofTH cells in nigra. In contrast to a 95% reduction in TH
cells in the lesion side nigra in animals with vehicle
treatment, 70% TH (+) neurons were lost in the lesioned
animals with 9cRA treatment. Similarly, there was about
99% reduction in KCl-evoked DA release in striatum in
vehicle -treated animals. The reduction in DA release
was only 66% after 9cRA treatment. Taken together, our
data suggest that 9cRA has a protective effect against 6-
OHDA injury in nigrostriatal dopaminergic neurons. It
Figure 7 9cRA treatment increased survival of TH cells in lesioned nigra. TH (+) cell number (A) in SN and (B) in VTA were counted using
unbiased stereology in 11 rats. (A) Injection of 6-OHDA reduced cell number of dopamine neurons in lesioned side (L) SN (p<0.001). Treatment
with 9cRA significantly increased dopamine cell number in the lesioned side (L) SN (p=0.026). No change was found in the contralateral
(non-lesioned, R) side SN (p=0.432). (B) TH cell number in A10. There is no significant difference after lesioning or after 9cRA treatment in VTA
(p=0.734).
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when 70-80% dopamine is depleted in patients [33,34].
In this study, we demonstrated that early treatment with
9cRA can reduce the death of DA neurons to 70%. It is
thus possible that post-treatment with 9cRA can be
beneficial to PD patients by slowing down its progressive
neurodegeneration.
We previously demonstrated that 9cRA can selectively
induce BMP7 mRNA expression in the brain. In this
study, we demonstrated that 9cRA reduced 6-OHDA
-mediated program cell death in culture. BMP7 has anti-
apoptotic properties. BMPs reduced caspase-3 activationand DNA fragmentation in the ischemic brain [35,36]
and attenuated dopaminergic neurotoxin -mediated
apoptosis and cell death in nigrostriatal DA neurons.
Interestingly, the reduction of TUNEL labeling by 9cRA
in stroke brain was antagonized by the BMP antagonist
noggin. Taken together, these data suggest that the pro-
tective effects of 9cRA may be indirectly mediated
through a BMP signaling mechanism.
RA analogs, such as 9cRA and atRA, are agonists for
RXR and RAR receptors. Compared to atRA, 9cRA is a
more selective agonist for RXR. Although both atRA
and 9cRA are neural protective against oxygen-glucose
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sensitivity of these two ligands have been seen in other
brain regions. Animals pretreated with 9cRA had lesser
cortical infarction than those treated with atRA after
middle cerebral artery occlusion [13]. Using RTPCR, we
also found that 9cRA is more potent than atRA in indu-
cing BMP7 (unpublished observation) and midkine [13]
expression in primary cortical cultures. We demon-
strated here that 9cRA is more potent than atRA, at 50
nM, against 6-OHDA –mediated neurodegeneration in
TH neuronal culture. Taken together, these differential
responses of 9cRA suggest that neuroprotection induced
by 9cRA involves activation of RXR.
Although 9cRA has a high affinity for RXR, it is not
detectable in adult brain tissue and, thus, may not be a
candidate endogenous ligand for this receptor. Studies
have indicated that the polyunsaturated fatty acids, such
as linolenic and docosahexaenoic acid, activate RXR
[10,38]. These polyunsaturated fatty acids have also been
reported to reduce neurodegeneration [39,40]. Future
experiments are required to investigate the mechanism
of protection induced by these polyunsaturated fatty
acids and their effects on RXR in animal model of PD.
There are several limitations to deliver drug to brain
days after onset of 6-OHDA lesioning. Drugs given sys-
temically may not easily cross the blood brain barrier
(BBB) and can be degraded through first pass metabol-
ism. Intracerebral delivery is not feasible for repeated
drug administration and may require chronic cannula-
tion. Previous reports have indicated that small mole-
cules can by-pass the BBB and reach brain parenchyma
non-invasively through an intranasal delivery. In this
study, 9cRA was given initially through i.c.v. and then
repeatedly through an intra-nasal route. We found that
intranasal administration of 9cRA increased brain 9cRA
level to 3 ng/g or 10 nM at 1 hour after delivery as
detected by LC-MS/MS analysis (Additional file 1:Figure
S1). No 9cRA was seen after vehicle treatment. Previous
studies have shown that 9cRA can activate RXR receptor
at this concentration [41].
In a preliminary study, we treated 6-OHDA –lesioned
rats with intranasal 9cRA without i.c.v injection from
day 7 to day 14. We did not find significant behavioral
improvement after intranasal 9cRA treatment and days
20 and 30, suggesting that a loading dose of 9cRA, given
i.c.v. on day 7 is required for this protective reaction.
Conclusion
We have demonstrated that 9cRA, given from 7th day to
14th day post 6-OHDA lesioning, reduced rotational be-
havior and loss of TH cells in nigra, while increased DA
release function in striatum. Our data suggest that 9cRA
has neuroprotective effects against neurodegeneration in
a rodent model of PD. The protection may be moreprominent if 9cRA is given earlier or prior to lesioning.
The effectiveness of 9cRA may be clinically useful for
patients at early stages of PD.
Methods
Primary cultures of rat ventral mesencephalon
Primary cultures were prepared from embryonic (E14-
15) ventral mesencephalon (VM) tissues obtained from
fetuses of timed-pregnant Sprague–Dawley rats (Charles
River Laboratories, Wilmington, MA), according to pub-
lished procedures with some modification. The whole
brain was removed aseptically and a small piece of tissue
comprising the VM was dissected. After removing the
blood vessels and meninges, pooled VM tissues were
trypsinized (0.25%; Invitrogen, Carlsbad, CA) with gentle
mixing for 15 min at 37°C. After rinsing off trypsin with
pre-warmed DMEM/F-12 (Invitrogen), cells were disso-
ciated by trituration, counted and plated into 96-well
(6.0 × 104/well) cell culture plates pre-coated with poly-
lysine (Sigma-Aldrich). The culture plating medium
consisted of Dulbecco’s modified Eagle medium/F12
supplemented with 10% heat-inactivated fetal bovine
serum, 1 mM L-glutamine and 2% B27 (Invitrogen). Cul-
tures were maintained at 37°C in a humidified atmos-
phere of 5% CO2 and 95% air. The cultures were fed by
exchanging 50% of media with feed media (Neurobasal
medium, Invitrogen) with 2% B27 with antioxidants
(+AO) supplement on DIV (days in vitro) 3 and 5. ON
DIV7, cultures were fed with feed media containing B27
supplement without antioxidants ((−) AO, Invitrogen).
Freshly made 6-hydroxydopamine (in 20 μM ascorbic
acid saline solution) or saline (with 20 μM ascorbic acid)
was added to the wells on DIV 10. After incubation for
2 hours, cultures were washed with (−)AO B27 3 times.
RA or vehicle was added to the well at the last wash.
Cells were returned to a 37°C incubator for 22 hours
then fixed with 4% paraformaldehyde (PFA) for
immunoreactivity.
In vitro immunoreactivity and quantitation
After removing PFA solution, cells were washed with PBS
and the fixed cultures were treated for 1 hour with block-
ing solution (2% BSA, 0. 1% Triton X-100 and 5% goat
serum in PBS). The cells were then incubated for 2 days at
4°C with a mouse monoclonal antibody against TH (1:500;
Chemicon, Temecula, CA, USA). The cells were then
rinsed three times in PBS. The bound primary antibody
was visualized using the AlexaFluor 488 goat anti-mouse
secondary (Invitrogen). Images were acquired using a
SPOT RT camera (Diagnostic Instruments, Inc., Sterling
Heights, MI) attached to a NIKON TE2000 inverted
microscope. TH+ cells were manually counted in 10x
images (4 fields per well of 96 well plate). All immuno-
reactive counts and quantitation were expressed as
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2–3 times with n=3-9 wells per group per experiment.
In vitro Terminal deoxynucleotidyl transferase
(TdT)-mediated dNTP nick -end labeling (TUNEL)
Cultures were assayed for DNA fragmentation using a
TUNEL-based method (In Situ Cell Death Detection Kit;
Roche, Indianapolis, IN). Briefly, 4% PFA fixed cells were
permeabilized in 0.1% Triton X-100 in 0.1% sodium cit-
rate for 2 min on ice. To label damaged nuclei, 50 μL of
the TUNEL reaction mixture was added to each sample
and kept at 37 °C in a humidified chamber for 60 min.
Procedures for positive and negative controls were car-
ried out as described in the manufacturer’s manual
(Roche). Controls consisted of not adding the label solu-
tion (terminal deoxynucleotidyl transferase) to the
TUNEL reaction mixture. Material was examined using
a Nikon TE2000 inverted microscope equipped with
fluorescence. TUNEL(+) cells were manually counted in
20x images (4 fields per well of 96 well plate).
Animals
Adult male Sprague Dawley rats from Charles River Lab
Inc. were used for this study. The use of animals was
approved by the Animal Care and Use Committee, Na-
tional Institute on Drug Abuse, IRP.
6-hydroxydopamine lesioning
Rats were anesthetized with chloral hydrate (400
mg/kg, i.p.) and placed in a stereotaxic frame. 6-
hydroxydopamine (2.27 μg/μl x 5 μl in 0.9% NaCl con-
taining 0.2 mg/ml ascorbic acid) was unilaterally
injected into the left medial forebrain bundle (−4.4 mm
AP, 1.2 mm ML relative to bregma and 8.4 mm below
skull) over 4 min. After injection, a piece of bone wax
(W810, Ethicon) was applied to the burr hole in the
skull to prevent efflux of the solution.
Behavioral measurement
Rotational behavior [42,43] was evaluated using a multi-
channel rotometer system (RotoMax, AccuScan Instru-
ments, Inc). Six days after 6-OHDA lesioning, all
animals were challenged with methamphetamine (2.5
mg/kg). Each animal was placed in a cylindrical test
chamber for 90 min. The highest consecutive net rota-
tions (ipsilateral -contralateral rotation) over 60 min
were used for analysis. Animals that rotated in excess of
300 turns/hour were selected for 9cRA or vehicle treat-
ment. Methamphetamine –induced rotation was re-
examined on 20 and 30 days after lesioning.
Administration of 9cRA
Animals were separated into 2 groups to receive 9cRA
or vehicle after rotation was measured by rotometer onday 6 after 6-OHDA lesioning. On the 7th day after
lesioning, animals were anesthetized with chloral hydrate
(0.4 g/kg, i.p.). 9cRA (1 μg/1μl × 20 μl, dissolved in 10%
DMSO, Sigma, pH 7.0) or vehicle (10% DMSO in saline
pH 7.0, 20 μL) was given intracerebroventricularly
through a Hamilton syringe. The coordinates for intra-
cerebroventricular injections were: 0.8 mm posterior to
the bregma, 1.5 mm lateral to the midline; 3.5 mm
below dura surface. The needle was retained in place for
5 min after injection. After injection, a piece of bone
wax (W810, Ethicon) was applied to the burr hole in the
skull to prevent efflux of the solution. Animals were
anesthetized with isoflurane for 5–10 min each day from
day 8 to day 14 after lesioning and were placed in a su-
pine position. 9cRA (conc=1 μg/1μl) or vehicle was
delivered into nostrils of each rat at dose of 20 μl daily
as previously described [44]. No difference in body
weight was found between animals treated with 9cRA or
vehicle.
KCl-evoked DA release
KCl –evoked DA release in striatum was measured at 2
months after lesioning. Animals were anesthetized using
urethane (1.25 g/kg, i.p.). In-vivo chronoamperometric
measurements of extracellular dopamine (DA) concen-
tration were performed as previously described (Zhou
et al., 1996). The recordings were taken at rates of 10 Hz
continuously using Nafion-coated carbon-fiber working
electrodes (tip = 30 μm; SF1A, Quanteon, Lexington,
Kentucky) and a microcomputer-controlled apparatus
(FAST system, Quanteon). The release of DA was mea-
sured by changes in extracellular DA concentration after
microinjection of KCl into the striatal parenchyma. KCl
(70 mM) in osmolarity balanced saline (79 mM NaCl
and 2 mM CaCl2) was locally applied through a micro-
pipette in the 150 to 225 nl range. The concentration
and volume of KCl solution in the pipette have been
previously reported to induce depolarization and release
of dopamine at dopaminergic nerve terminals in vivo.
The working electrode and the micropipette were
mounted together with sticky wax; tips were separated
by 150 μm. The electrode/pipette assembly was lowered
into striatum (AP 0–0.5 mm, M/L 2.5 mm relative to
bregma and 3.5 to 7.0 mm below the dura). Local appli-
cation of KCl from the micropipette was performed by
pressure ejection using a pneumatic pump (BH2, Med-
ical System). The ejected volume was monitored by
recording the change in the fluid meniscus in the pipette
before and after ejection using a dissection microscope.
Tyrosine hydroxylase (TH) immunoreactivity
Animals were euthanized >2 month after lesioning. Ani-
mals were anesthetized with chloral hydrate (400 mg/kg
i.p.) and perfused transcardially with saline followed by
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0.1 M; pH 7.2). The brains were dissected, post-fixed in
PFA for 18–20 hours, and transferred to 18% sucrose
in 0.1 M PB for at least 16 hours. Serial sections of the
entire brain were cut at 40 μm thickness in a cryostat.
One series from every sixth section was stained for TH.
In order to control for staining variability, specimens
from all experimental groups were included in every
batch and reacted together in a net well tray under the
same conditions. Sections were rinsed in 0.1M phos-
phate buffer (PB), blocked with 4% bovine serum albu-
min (BSA) and 0.3% Triton x-100 in 0.1M PB. Sections
were then incubated in a primary antibody solution
mouse monoclonal anti-TH diluted in 4% BSA and
0.3% Triton x-100 in 0.1M PB, concentration 1:100
(Chemicon, Temecula, CA) for 17–19 hours at 4°C.
Sections were then rinsed in 0.1M PB and incubated in
biotinylated horse anti-mouse IgG in the buffer (1:200;
Vector Laboratories, Burlingame CA) for 1 hour, fol-
lowed by incubation for 1 hour with avidin-biotin-
horseradish peroxidase complex. Staining was developed
with 2,30 diaminobenzidine tetrahydrochloride (0.5 mg/
ml in 50 mM Tris–HCl buffer 7.4). Control sections
were incubated without primary antibody. Sections were
mounted on slides, and cover slipped.
Stereological analysis
The total number of TH (+) neurons was estimated bi-
laterally every 6th section through the extent of the mid-
brain for adult control and 6-OHDA treated rats. The
substantia nigra compacta (SNc) was outlined under a
low magnification objective (5x) following landmarks
from the Paxinos and Watson rat atlas (Paxinos, G,
2004) and the stereologic analysis was performed under
the 40x objective of a Leica DM5000B microscope (Leica
Microsystems, Bannockburn, IL) and analyzed with
StereoInvestigator software (MBF Bioscience, Williston,
VT). The optical fractionator probe was used to generate
an estimate of the total number of TH (+) neurons in
the SNc. For each tissue section analyzed, section thick-
ness was assessed in each sampling site and guard zones
of 2.5 μm were used. Systematic random sampling de-
sign was performed and generated with the following
stereologic parameters: grid size: 270 × 185μm, counting
frame: 100 × 100μm and dissector height of 25 μm. Our
criterion for counting an individual TH (+) neuron was
the presence of its nucleus. Coefficients of error were
calculated and values <0.10 were accepted.
Additional file
Additional file 1: Figure S1. Increase 9cRA level in brain after intranasal
delivery of 9cRA. A total of 12 rats were given either 9cRA (20 ug per
animal) or vehicle intranasally. Brain tissues were harvested at 1, 2 and 4hours after administration. Tissues were extracted and 9cRA levels in
brain homogenates were detected by Mass spectrometry as previously
described (Kane, A. Biochem J. 388,363-369, 2005). No detectable 9cRA
was found in vehicle treated rats. There is a significant increase in 9cRA
level at one and 2 hours after 9cRA administration (p<0.05, one way
ANOVA). Brain 9cRA level returned to the basal level at 4 hours after
administration.
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